The present invention provides antibodies and fragments thereof that bind to Dkk-1 and, in particular, to humanized antibodies and fragments thereof that bind to Dkk-1 and, even more particularly to fully humanized antibodies and immunologically functional fragments that bind to Dkk-1. Also provided are antibodies and fragments thereof which compete with the binding of an anti-mouse Dkk-1 monoclonal antibody for binding to Dkk-1+ cells. Also provided are nucleic acids encoding anti-Dkk-1 antibodies or fragments thereof, as well as expression vectors and host cells incorporating these nucleic acids for the recombinant expression of anti-Dkk-1 antibodies and fragments thereof. Also provided are methods of preparing the antibodies and fragments thereof of the invention. Also provided are bone anabolic agents. Pharmaceutical compositions comprising the antibodies or fragments thereof of the invention are also provided. Further provided are methods of treating diseases, conditions and disorders, such as bone disorders, which result in a loss of bone. Methods of treating or preventing a loss of bone mass, methods of inducing increased bone mass, and methods of inducing Wnt activity are also provided.La présente invention concerne des anticorps et des fragments de ceux-ci pouvant se lier au Dkk-1 et, en particulier, des anticorps humanisés et des fragments de ceux-ci pouvant se lier au Dkk-1 et, encore plus particulièrement des anticorps entièrement humanisés et des fragments immunologiquement fonctionnels pouvant se lier au Dkk-1. Linvention concerne également des anticorps et des fragments de ceux-ci pouvant être en compétition avec la liaison dun anticorps monoclonal anti-Dkk-1 de souris en ce qui concerne la liaison aux cellules Dkk-1+. Linvention concerne également des acides nucléiques codant pour les anticorps anti-Dkk-1 ou les fragments de ceux-ci, ainsi que des vecteurs dexpression et des cellules hôtes incorporant ces acides nucléiques destinés à lexpression reco
